2-Bromo-9,10-diphenylanthracene | CAS:201731-79-5

We serve 2-Bromo-9,10-diphenylanthracene CAS:201731-79-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromo-9,10-diphenylanthracene

Chemical Name:2-Bromo-9,10-diphenylanthracene
CAS.NO:201731-79-5
Synonyms:2-bromo-9,10-diphenyl-anthracene
Anthracene,2-bromo-9,10-diphenyl
2-bromo-9,10-diphenyl-9,10-dihydroanthracene
Molecular Formula:C26H17Br
Molecular Weight:409.31700
 
Physical and Chemical Properties:
Density:1.344
Boiling point:508.6ºC
Flash point:1.709ºC
 
Specification:
Appearance:Yellow solid
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 2-Bromo-9,10-diphenylanthracene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromo-9,10-diphenyl-9,10-dihydroanthracene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Bromo-9,10-diphenylanthracene Use and application,2-Bromo-9,10-diphenylanthracene technical grade,usp/ep/jp grade.


Related News: Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.Ethyl 5-oxo-1-phenyl-2-pyrazoline-3-carboxylate manufacturer Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.4,7-Dichloroquinoline supplier There are also new directives that relate to US citizens.4-Amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide vendor The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.